The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation
Open accessAbstract
// Zhiqiang Liu 1,* , Jingda Xu 1,* , Jin He 1 , Huan Liu 1 , Pei Lin 2 , Xinhai Wan 3 , Nora M. Navone 3 , Qiang Tong 4 , Larry W. Kwak 1 , Robert Z. Orlowski 1 and Jing Yang 1 1 Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 Department of Genitourinary Medical Oncology-Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 4 Children’s Nutrition Research Center, Baylor College of Medicine, Houston, Texas, USA * These authors have contributed equally to this work Correspondence to: Jing Yang, email: // Keywords : multiple myeloma, adipocytes, autophagy, apoptosis, chemotherapy resistance Received : June 30, 2015 Accepted : September 05, 2015 Published : October 07, 2015 Abstract A major problem in patients with multiple myeloma is chemotherapy resistance, which develops in myeloma cells upon interaction with bone marrow stromal cells. However, few studies have determined the role of bone marrow adipocytes, a major component of stromal cells in the bone marrow, in myeloma chemotherapy resistance. We reveal that mature human adipocytes activate autophagy and upregulate the expression of autophagic proteins, thereby suppressing chemotherapy-induced caspase cleavage and apoptosis in myeloma cells. We found that adipocytes secreted known and novel adipokines, such as leptin and adipsin. The addition of these adipokines enhanced the expression of autophagic proteins and reduced apoptosis in myeloma cells. In vivo studies further demonstrated the importance of bone marrow-derived adipocytes in the reduced response of myeloma cells to chemotherapy. Our findings suggest that adipocytes, adipocyte-secreted adipokines, and adipocyte-activated autophagy are novel targets for combatting chemotherapy resistance and enhancing treatment efficacy in myeloma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the use and interpretation of assays for monitoring autophagy
Klionsky, D. J., Abdalla, F. C., Abeliovich, H., Abraham, R. T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J. A., et al. (2012) · Autophagy · doi:10.4161/auto.19496 · Cited by 4,330 · cited 3×
“To determine whether adipocytes inhibit MM cell apoptosis by coming into direct contact with MM cells, we co-cultured MM cells and adipocytes and separated them, using transwell inserts [39], in a medium containing melphalan.”
InfluentialSelf-citationSialin ( SLC17A5 ) functions as a nitrate transporter in the plasma membrane
Qin, L., Liu, X., Sun, Q., Fan, Z., Xia, D., Ding, G., Ong, H. L., Adams, D., Gahl, W. A., Zheng, C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116633109 · Cited by 216
Self-citation
Cited by
Adipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 522
Tumour fatty acid metabolism in the context of therapy resistance and obesity
Hoy, A. J., Nagarajan, S. R., & Butler, L. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00388-4 · Cited by 392
Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
Harmer, D., Falank, C., & Reagan, M. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00788 · Cited by 307
The autophagic network and cancer
Rybstein, M. D., Bravo-San Pedro, J. M., Kroemer, G., & Galluzzi, L. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0042-2 · Cited by 289
Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease
Liu, H., He, J., Koh, S. P., Zhong, Y., Liu, Z., Wang, Z., Zhang, Y., Li, Z., Tam, B. T., Lin, P., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau9087 · Cited by 113
Self-citationDrug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65
Pang, J., Shi, Q., Liu, Z., He, J., Liu, H., Lin, P., Cui, J., & Yang, J. (2017) · Haematologica · doi:10.3324/haematol.2016.154062 · Cited by 57
Self-citationLiu, Z., Liu, H., He, J., Lin, P., Tong, Q., & Yang, J. (2020) · Science Signaling · doi:10.1126/scisignal.aay8203 · Cited by 49
“Human MSCs were generated from BM mononuclear cells from fetal bones of healthy human donors, characterized using flow cytometry, and labeled with antibodies against MSC markers (CD44, CD90, and CD166) (41).”
MethodSelf-citationFairfield, H., Costa, S., Falank, C., Farrell, M., Murphy, C. S., D’Amico, A., Driscoll, H., & Reagan, M. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.584683 · Cited by 42
Zhang, X., Tian, L., Majumdar, A., & Scheller, E. L. (2024) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2024.tb00300.x · Cited by 18
Lemaitre, L., Do Souto Ferreira, L., Joubert, M.-V., Avet-Loiseau, H., Martinet, L., Corre, J., & Couderc, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113854 · Cited by 13
Metadata
- Authors
- Liu, Z., Xu, J., He, J., Liu, H., Lin, P., Wan, X., Navone, N. M., Tong, Q., Kwak, L. W., Orlowski, R. Z., & Yang, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-07
- Volume
- 6
- Issue
- 33
- Pages
- 34329-34341
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2264691042
- Cited by
- 164
- References
- 2
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.